Characterization of intrinsic and acquired resistance to KRASG12C inhibitors across a broad collection of cancer cell line models

Krazati (adagrasib) - BMS

Ojemda (tovorafenib) - Servier

ulixertinib (BVD-523) - BioMed Valley Discoveries

Lumakras (sotorasib) - Amgen

belvarafenib (RG6185) - Hanmi

divarasib (RG6330) - Roche

Mekinist (trametinib) - Novartis, BeOne Medicines

https://www.abstractsonline.com/pp8/#!/21436/presentation/5076

Jeffrey J. Kooijman; Kirsten J. W. Kevenaar; Imke P. M. Smits; Daphne J. F. Kluitmans; Laura D. R. van Zelst; Bente Timmers; Tsang W. Lam; Jeroen A. D. M. de Roos; Yvonne Grobben; Janneke J. T. M. Melis; Guido J. R. Zaman; Jorg C. J. Benningshof

Mar 18, 2026